Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LIPC | P11150 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435117 | 0.91 | FFAR1 (0.46) | GRIN1GRIN2BFFAR4PPARGFFAR1 | |
| SCHEMBL3434891 | 0.89 | FFAR4 (0.44) | FFAR4PPARGPIN1HCRTR1FFAR1 | |
| SCHEMBL3350646 | 0.86 | ALDH1A1 (0.42) | PIN1 | |
| SCHEMBL3473519 | 0.85 | FFAR1 (0.44) | GRIN1GRIN2BFFAR4PPARGFFAR1 | |
| SCHEMBL3346223 | 0.85 | PIN1 (0.46) | FFAR4PPARGPIN1HCRTR1FFAR1 | |
| SCHEMBL15147639 | 0.84 | PIN1 (0.43) | GRIN1GRIN2BPIN1HCRTR1 | |
| SCHEMBL3350638 | 0.84 | PIN1 (0.45) | GRIN1GRIN2BPIN1 | |
| SCHEMBL3474846 | 0.84 | PPARG (0.44) | PPARG | |
| SCHEMBL3475274 | 0.82 | FFAR1 (0.43) | GRIN1GRIN2BFFAR4PPARGPIN1 | |
| SCHEMBL3473822 | 0.81 | FFAR1 (0.43) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | claimed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | claimed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2010053757-A1 | 2 -OXOQUINOXALIN BLOCKERS OF THE LATE SODIUM CHANNEL | GILEAD PALO ALTO, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | GRIN1 1435/4885GRIN2B 2067/4885FFAR4 363/4885 |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | GRIN1 1435/4885GRIN2B 2067/4885FFAR4 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.